Stockscreener 앱 받기
5.71
0.35%
0.02
시간 외 거래:
5.75
0.04
+0.70%
전일 마감가:
$5.69
열려 있는:
$5.7
하루 거래량:
4.99M
Relative Volume:
0.64
시가총액:
$1.74B
수익:
$79.21M
순이익/손실:
$-143.96M
주가수익비율:
-11.91
EPS:
-0.4796
순현금흐름:
$-189.60M
1주 성능:
+7.53%
1개월 성능:
-27.26%
6개월 성능:
+57.73%
1년 성능:
+27.74%
1일 변동 폭
$5.51
$5.87
1주일 범위
$4.98
$5.87
52주 변동 폭
$2.745
$8.44
앱셀레라바이오로직스 Stock (ABCL) Company Profile
명칭
Abcellera Biologics Inc
전화
(604) 559-9005
주소
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
5.71 | 1.60B | 79.21M | -143.96M | -189.60M | -0.4796 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
앱셀레라바이오로직스 Stock (ABCL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | 재개 | Leerink Partners | Outperform |
| 2024-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-02-22 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 재개 | Piper Sandler | Overweight |
| 2023-02-28 | 개시 | Cowen | Outperform |
| 2022-12-15 | 개시 | Goldman | Buy |
| 2022-11-16 | 개시 | Truist | Buy |
| 2021-12-21 | 개시 | The Benchmark Company | Buy |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-01-05 | 개시 | Berenberg | Buy |
| 2021-01-05 | 개시 | Credit Suisse | Outperform |
| 2021-01-05 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | Stifel | Buy |
모두보기
앱셀레라바이오로직스 주식(ABCL)의 최신 뉴스
Abcellera Biologics Inc (ABCL) Income Statement - TradingKey
ABCL|Abcellera Biologics Inc|Price:5.245|Chg%:-0.065 - TradingKey
Abcellera Biologics Inc (ABCL) Cash Flow - TradingKey
Abcellera Biologics Inc (ABCL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ABCL|Abcellera Biologics Inc|Price:5.310|Chg%:-0.360 - TradingKey
Abcellera Biologics Inc (ABCL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost - Stocktwits
Abcellera Biologics, Inc. (ABCL) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (ABCL) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics Inc (ABCL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AbCellera Biologics Market Sentiment - Benzinga España
AbCellera Biologics, Inc. Revenue Breakdown – DUS:8QQ - TradingView
Abcellera Biologics Inc (ABCL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Playing The Biotech Breakout With Insiders - Seeking Alpha
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers - marketscreener.com
Abcellera Biologics, Inc. (ABCL) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (ABCL) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (ABCL) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (8QQ) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (8QQ) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (8QQ) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (8QQ) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (8QQ) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (8QQ) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (8QQ) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (8QQ) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (8QQ) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (8QQ) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (8QQ) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Abcellera Biologics, Inc. (8QQ) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Does AbCellera’s New Board Appointment Reframe Its Execution Story for Investors in ABCL? - simplywall.st
Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade - MSN
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11 By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11 - Investing.com UK
symbol__ Stock Quote Price and Forecast - CNN
JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13 - Moomoo
ABCL Stock Price and Chart — NASDAQ:ABCL - TradingView
Weekly Recap: Lynn Seely board appointment and Benchmark upgrade to Buy - TradingView
AbCellera Biologics Stock (ABCL) Opinions on Jazz Partnership and Analyst Upgrade - Quiver Quantitative
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year? - MSN
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains? - MSN
AbCellera Biologics (ABCL) TD Cowen 46th Annual Health Care Conference Summary - Quartr
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 - BNN Bloomberg
Are you looking for a top momentum pick? Why AbCellera Biologics Inc. (ABCL) is a great choice - MSN
AbCellera Biologics (ABCL) Q4 2024 earnings summary - Quartr
Press Release: AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 - Moomoo
AbCellera Appoints Dr. Victor Sandor to its Board of Directors - AOL.com
Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choice - Yahoo Finance
Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target Is $11 - Moomoo
AbCellera Biologics Price Target Announced at $11.00/Share by Benchmark - Moomoo
앱셀레라바이오로직스 (ABCL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.44%
0.02%
자본화:
|
볼륨(24시간):